Advanced cell therapy isn't just about replacing lost cells. Transplanted, genetically engineered cells can be programmed to produce and secrete therapeutics locally. This turns them into a delivery platform that solves the critical challenge of the blood-brain barrier for large molecules.
While small molecules might eventually cure other conditions, brain diseases are uniquely defined by the physical loss of cells. Therefore, cell replacement therapy isn't just another approach; it's the most logical and potentially only curative long-term solution.
Prior therapeutic strategies were flawed. Symptomatic treatments squeeze more function from the few remaining neurons until they also die. Disease-modifying drugs, like antibodies, are often ineffective because the blood-brain barrier allows less than 0.1% to reach the brain.
The core issue in neural cell therapy isn't just cell replacement. The diseased brain environment destroys most transplanted cells, with only 3% surviving the initial process and just 10% of those becoming functional. The key is protecting the new cells.
Instead of building costly in-house GMP capabilities early on, a more effective strategy is to concentrate on the core preclinical science. By partnering with established CDMOs and consultants for the translation to GMP, startups can de-risk development and accelerate their timeline to an IND filing.